Lin Wang
About Lin Wang
Lin Wang is the Director of Global HEOR Cell Therapy at Bristol Myers Squibb, with extensive experience in health economics and outcomes research across multiple therapeutic areas.
Current Role at Bristol Myers Squibb
Lin Wang is currently the Director of Global HEOR Cell Therapy at Bristol Myers Squibb. In this role, Wang oversees health economics and outcomes research (HEOR) related to cell therapy. This position involves strategic oversight of economic evaluation studies, the generation of real-world evidence, and the assessment of treatment outcomes to support value demonstration and reimbursement discussions for cell therapy products globally.
Previous Positions at Bristol Myers Squibb
Prior to Lin Wang's current role, Wang served as Director, Global HEOR Hematology at Bristol Myers Squibb from 2022 to 2024. This position focused on health economics and outcomes research in the field of hematology. Wang was responsible for overseeing studies that assessed both the economic impact and clinical effectiveness of hematology treatments, contributing to strategic decision-making processes and policy development in the area of blood disorders.
Academic Background and Credentials
Lin Wang holds a Doctorate Degree in Epidemiology from Johns Hopkins Bloomberg School of Public Health, completed from 2018 to 2021. Wang also earned a Master's Degree in Epidemiology from the same institution, completed between 2016 and 2018. Wang is a member of the Delta Omega Alpha Honorary Society at Johns Hopkins School of Public Health, signaling exceptional academic performance. Additionally, Wang holds a Doctor of Medicine (MD) from Central South University.
Professional Experience in Health Outcomes Research
Lin Wang's extensive experience in health economics and outcomes research spans multiple high-profile roles. Notably, Wang worked as an Associate Principal Scientist/Associate Director of Global HEOR Oncology at Merck from 2021 to 2022, focusing on oncology treatments. Prior to that, Wang served as a Research Analyst/Manager in Global HEOR Neuroscience at AbbVie, and as a Pre Doctoral Fellow at PhRMA Foundation. Wang's expertise is marked by work on clinical trial design, systematic literature review, network meta-analysis, and economic evaluation.
Commitment to Patient Safety and Risk Management
Lin Wang has demonstrated a strong commitment to patient safety and effective risk management strategies. Wang manages three legacy Celgene REMS programs that include Elements to Assure Safe Use (ETASU): Lenalidomide REMS, POMALYST REMS, and THALOMID REMS. Wang has collaborated with the FDA to develop a risk management system for thalidomide, ensuring its safe use for patients with serious unmet medical needs. Wang's work in this area underscores a dedication to balancing treatment efficacy with rigorous safety protocols.